.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,736,121

« Back to Dashboard

Details for Patent: 5,736,121

Title: Stabilized homogenous suspensions as computed tomography contrast agents
Abstract:Novel stabilized suspensions of a gas as diagnostic contrast agents, including computed tomography (CT) and magnetic resonance (MR) contrast agents. In preferred embodiments, the suspensions comprise stabilized gas filled microspheres. Also in some preferred embodiments, at least a portion of the gas is derived from a gaseous precursor.
Inventor(s): Unger; Evan C. (Tucson, AZ)
Assignee: ImaRx Pharmaceutical Corp. (Tucson, AZ)
Filing Date:May 19, 1995
Application Number:08/444,754
Claims:1. A method of providing an image of an internal region of a patient comprising (i) administering to the patient a stabilized, substantially homogeneous, aqueous suspension of a gaseous precursor, (ii) allowing said gaseous precursor to undergo a phase transition from a liquid to a gas in vivo, and (iii) scanning the patient using computed tomography to obtain visible images of the region, wherein said gaseous precursor comprises a perfluorocarbon and said suspension is in the form of an emulsion.

2. A method according to claim 1 wherein said gaseous precursor undergoes a phase transition from a liquid to a gaseous state at near the normal body temperature of the patient.

3. A method according to claim 1 wherein said suspension has a negative density of about -40 HU or less.

4. A method according to claim 3 wherein said suspension has a negative density of about -50 HU or less.

5. A method according to claim 4 wherein said suspension has a negative density of about -100 HU or less.

6. A method according to claim 5 wherein said suspension has a negative density of about -500 HU or less.

7. A method according to claim 1 wherein said suspension is stabilized with a stabilizing material.

8. A method according to claim 7 wherein said stabilizing material comprises a surfactant.

9. A method according to claim 8 wherein said surfactant is selected from the group consisting of anionic, cationic, zwitterionic and nonionic surfactants.

10. A method according to claim 9 wherein said surfactant comprises a nonionic surfactant.

11. A method according to claim 10 wherein said nonionic surfactant is selected from the group consisting of a polyoxyethylene-polyoxypropylene glycol block copolymer and a sorbitan fatty acid ester.

12. A method according to claim 11 wherein said perfluorocarbon is selected from the group consisting of perfluoropentane, perfluorohexane, perfluoroheptane and perfluorooctane.

13. A method according to claim 12 wherein said perfluorocarbon comprises perfiuoropentane.

14. A method according to claim 1 wherein said suspension further comprises a thickening agent.

15. A method according to claim 14 wherein said thickening agent is selected from the group consisting of starches, gums, pectin, casein, agarose, gelatin, carrageenan and cellulose derivatives.

16. A method according to claim 15 wherein said thickening agent is selected from the group consisting of gums, carrageenan and cellulose additives.

17. A method according to claim 16 wherein said gum comprises xanthan gum.

18. A method according to claim 16 wherein said cellulose derivative is selected from the group consisting of methyl cellulose and carboxymethyl cellulose.

19. A method according to claim 18 wherein said cellulose derivative comprises methyl cellulose.

20. A method according to claim 1 wherein said suspension further comprises a dispersing agent.

21. A method according to claim 20 wherein said dispersing agent comprises a polymeric siloxane compound.

22. A method according to claim 21 wherein said polymeric siloxane compound is substantially completely alkylated with alkyl groups.

23. A method according to claim 22 wherein said alkyl groups comprise lower alkyl groups.

24. A method according to claim 23 wherein said lower alkyl groups are methyl groups.

25. A method according to claim 24 wherein said polymeric siloxane compound is .alpha.-(trimethylsilyl)-.omega.-methylpoly[oxy(dimethylsilylene)].

26. A method according to claim 1 wherein said suspension further comprises a compound selected from the group consisting of lipids, ingestible oils, viscosity modifiers, emulsifying and/or solubilizing agents, suspending or viscosity-increasing agents, synthetic suspending agents, and tonicity-raising agents.

27. A method according to claim 1 wherein the region comprises the vasculature region.

28. A method according to claim 1 wherein the region comprises the cardiovascular region.

29. A method according to claim 1 wherein the region comprises the gastrointestinal region.

30. A method according to claim 1 wherein said scanning is of a region of a patient selected from the group consisting of the intranasal tract, the auditory canal, the intraocular region, the intraperitoneal region, the kidneys, the urethra and the genitourinary tract.

31. A method for diagnosing the presence of diseased tissue in a patient comprising (i) administering to the patient a stabilized, substantially homogeneous, aqueous suspension of a gaseous precursor, (ii) allowing said gaseous precursor to undergo a phase transition from a liquid to a gas in vivo, and (iii) scanning the patient using computed tomography to obtain visible images of any diseased tissue in the patient, wherein said gaseous precursor comprises a perfluorocarbon and said suspension is in the form of an emulsion.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc